IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

ClinicalTrials.gov ID: NCT06119685

Public ClinicalTrials.gov record NCT06119685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.

Study identification

NCT ID: NCT06119685
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Indapta Therapeutics, INC.; Industry
Enrollment: 128 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 24, 2023
Primary completion: Dec 29, 2025
Completion: Dec 30, 2029
Last update posted: Jun 2, 2025

2023 – 2029

United States locations

U.S. sites: 12
U.S. states: 12
U.S. cities: 12

Facility	City	State	ZIP	Site status
Valkyrie Clinical Trials	Los Angeles	California	90670	Recruiting
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center	Lake Mary	Florida	32746	Withdrawn
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
NYP/Weill Cornell Medical Center	New York	New York	10065	Withdrawn
Atrium Health Wake Forest Baptist	Winston-Salem	North Carolina	27157	Recruiting
University Hospitals Cleveland	Cleveland	Ohio	44106	Recruiting
Providence Cancer Institute Franz Clinic	Portland	Oregon	97213	Withdrawn
Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
NEXT Oncology Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06119685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 2, 2025 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06119685 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →